Prolyl hydroxylase domain inhibitor treatment to improve survivability of hemorrhagic shock

A method for reducing organ failure and/or improving survivability in a patient with severe hemorrhage or hemorrhagic shock, comprising steps of:

• a. administering resuscitation fluid through intravenous route, optionally administering an aliquot of 250 mL repeatedly up to 2000 mL while continuously monitoring a systolic blood pressure, radial pulse, and/or sensorium signs,
• b. administering at least one composition comprising a therapeutically effective amount of anti-hemorrhage agent one time or multiple times, and
• c. optionally administering vasopressors and/or inotropic agents;
• wherein the resuscitation fluid comprises whole blood, plasma/red blood cells/platelets, crystalloid solution;
• colloid solution comprising human albumin, hydroxyl ethyl starch (HES), or dextran;
• hypertonic saline (5 ml/kg NaCl 7.5%) with or without dextran;
• or oxygen-carrying blood substitutes, or a combination thereof;
• wherein the anti-hemorrhage agent comprises prolyl hydroxylase domain inhibitor (PHDi), antifibrinolytic agent, bradykinin receptor antagonist, or combination thereof that can be co-administered, and
• wherein the vasopressor or inotropic is vasopressin, norepinephrine, epinephrine, dobutamine, or their synthetic equivalents;
• wherein, the resuscitation fluid (i) is fresh whole blood or plasma/red blood cells/platelets, optionally at a ratio of about 1:about 1:about 1;
• or (ii) is a colloid solution comprising human albumin, and, optionally, wherein the resuscitation fluid further comprises fibrinogen.